Regorafenib más Nivolumab en pacientes con cáncer gástrico o colorrectal avanzado: un ensayo de fase Ib abierto, con escalada y expansión de dosis (REGONIVO, EPOC1603)

Fukuoka et al. (martes) estudiaron esta cuestión.

www.synapsesocial.com/papers/69dabe5d4e9a02dbaa68424d — DOI: https://doi.org/10.1200/jco.19.03296

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Role of the Microenvironment in Liver Metastasis: From Pre- to Prometastatic Niches· 2016 · 317 citations
2. PD-1 ⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer· 2019 · 1,015 citations
3. Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade· 2018 · 170 citations
4. Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma· 2017 · 304 citations
5. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial· 2012 · 2,878 citations